<a href="https://www.fiercebiotech.com/biotech/gsks-700m-alector-bet-blows-alzheimers-drug-flunks-phase-2" hreflang="en">GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2</a>
GSK and Alector have halted a phase 2 trial for their Alzheimer’s drug candidate nivisnebart after it was deemed unlikely to meet its primary endpoint, effectively ending their partnership. This follows a series of failures for Alector's drug candidates targeting neurodegenerative diseases, raising skepticism about the viability of their therapeutic approach.
For a professional tracking healthtech and biotech trends, the key insight is the increasing skepticism around targeting progranulin for Alzheimer's and dementia treatment, as demonstrated by the failure of GSK and Alector's trials. This highlights a potential shift in focus for future research and investment, possibly towards technologies that can effectively cross the blood-brain barrier, given the promising preclinical data on Alector's next wave of assets.